Dyspareunia in women

Epidemiology & Risk Factors

• Prevalence: Affects 10–20% of reproductive-aged and up to 50% of postmenopausal women.
• Risk Factors:
  • Hypoestrogenism: Menopause, lactation/postpartum, bilateral oophorectomy, anti-estrogen therapy (e.g., Tamoxifen, Aromatase inhibitors).
  • Structural/Anatomic: Endometriosis, pelvic adhesions, uterine leiomyomas, adenomyosis, retroverted uterus.
  • Infectious/Inflammatory: Recurrent vulvovaginitis (Candidiasis, Trichomoniasis, BV), Pelvic Inflammatory Disease (PID), Lichen Sclerosus, Lichen Planus.
  • Psychological/Musculoskeletal: High pelvic floor muscle tone, history of sexual trauma, anxiety/depression.

---

Clinical Features

• Superficial / Introital Dyspareunia (pain localized to vulva/introitus upon initial entry/touch):
  • Genitourinary Syndrome of Menopause (GSM) / Atrophic Vaginitis: Vaginal dryness, pruritus, dysuria, pale/smooth mucosa with loss of rugae, petechiae.
  • Lichen Sclerosus: Severe pruritus, porcelain-white atrophic plaques (“cigarette-paper skin”), loss of labia minora/clitoral hood architecture (resorption), anal fissures; spares the vagina.
  • Vulvodynia / Vulvar Vestibulodynia: Severe burning pain elicited by light contact (tampon use, tight clothing, sexual contact); (+) Cotton-swab/Q-tip test at the vestibule.
  • Genito-Pelvic Pain/Penetration Disorder (Vaginismus): Involuntary perineal/pelvic floor muscle spasm preventing vaginal entry; normal pelvic exam anatomy when relaxed.
• Deep Dyspareunia (pain provoked by deep penile thrusting/cervical movement):
  • Endometriosis: Deep pelvic aching, cyclic pelvic pain, dysmenorrhea, dyschezia, infertility; tender uterosacral ligament nodularity, fixed/retroverted uterus.
  • PID: Subacute/acute lower abdominal pain, purulent discharge, cervical motion tenderness (Chandelier sign), adnexal tenderness.
  • Adenomyosis: Multiparous pt >40 yo with heavy menstrual bleeding (HMB), dysmenorrhea, and a globular, symmetrically enlarged, soft/boggy, tender uterus.
  • Interstitial Cystitis / Bladder Pain Syndrome: Suprapubic pain worsening with bladder filling and relieved by voiding, urinary urgency/frequency.

---

Diagnosis

• Initial / Screening:
  • Detailed history: Distinguish superficial/introital vs deep pain; relationship to menses/urination/defecation.
  • Cotton-swab test (Q-tip test): Lightly touch vestibular glands at 1, 5, 7, and 11 o’clock to localize superficial allodynia.
  • Speculum & Bimanual Exam: Assess mucosal integrity, vaginal pH, discharge, cervical motion tenderness, and pelvic organ mobility/masses.
• Key Labs:
  • Vaginal pH: Normal (3.8–4.5) in Vulvodynia/Vaginismus; Elevated (>4.5–5.0) in GSM, BV, and Trichomoniasis.
  • Wet mount / KOH prep / NAAT: Rule out Candida (pseudohyphae), Trichomonas (motile flagellates), Chlamydia trachomatis, and Neisseria gonorrhoeae.
  • Urinalysis & Urine Culture: Rule out UTI/infectious cystitis.
• Imaging:
  • Transvaginal Ultrasound (TVUS): Initial imaging for deep dyspareunia to identify endometriomas, adenomyosis, leiomyomas, or tubo-ovarian abscesses (TOA).
• Confirmatory / Gold Standard:
  • Endometriosis: Laparoscopy with direct visualization and biopsy of implants (“powder-burn” lesions).
  • Lichen Sclerosus / Malignancy: Vulvar punch biopsy (indicated for atypical features, uncertain diagnosis, or steroid-refractory lesions to rule out SCC).
  • Interstitial Cystitis: Clinical diagnosis of exclusion; Cystoscopy with hydrodistention shows Hunner lesions/glomerulations (if diagnosis is unclear).

---

Differential Diagnostics

• GSM vs Lichen Sclerosus:
  • GSM: Affects vagina and vulva; responds rapidly to vaginal estrogen; normal vulvar architecture.
  • Lichen Sclerosus: Spares vagina; causes structural loss (labia minora resorption, clitoral phimosis); requires high-potency topical steroids.
• Vaginismus vs Vulvodynia:
  • Vaginismus: Marked physical resistance/muscle spasm to any penetration; no focal mucosal pain on Q-tip touch.
  • Vulvodynia: Severe localized pain on gentle vestibular touch; muscle spasm is secondary, not the primary defect.
• Endometriosis vs Adenomyosis:
  • Endometriosis: Involves extrauterine implants; fixed/nodular uterosacral ligaments, retroverted uterus; pain is often focal/asymmetric.
  • Adenomyosis: Confined to myometrium; uterus is uniformly enlarged, globular, soft, and diffusely tender.
• PID vs Interstitial Cystitis:
  • PID: Acute/subacute, systemic signs (fever, leukocytosis, elevated ESR/CRP), purulent cervicitis, (+) cervical motion tenderness.
  • Interstitial Cystitis: Chronic (>6 weeks), pain correlates with bladder volume (relieved after urination), sterile pyuria/negative cultures.

---

Management

• Superficial Etiologies:
  • GSM / Atrophic Vaginitis:
    1. First-line: Non-hormonal vaginal lubricants (during intercourse) & long-acting vaginal moisturizers (regular use).
    2. Second-line (Hormonal): Low-dose local vaginal estrogen (cream, tablet, or estradiol ring); vaginal DHEA (Prasterone) or oral SERM (Ospemifene).
  • Lichen Sclerosus:
    1. First-line: High-potency topical corticosteroids (e.g., Clobetasol propionate 0.05% ointment).
    2. Second-line: Topical calcineurin inhibitors (e.g., Tacrolimus).
  • Vulvodynia / Vestibulodynia:
    1. First-line: Vulvar hygiene measures, pelvic floor PT, topical Lidocaine 5% ointment applied 30 min before intercourse.
    2. Second-line: Oral neuromodulators (TCAs like Amitriptyline, or Gabapentin).
    3. Refractory: Surgical vestibulectomy (carefully selected severe cases).
  • Genito-Pelvic Pain/Penetration Disorder (Vaginismus):
    1. First-line: Pelvic floor physical therapy + Graduated vaginal dilator therapy + Cognitive Behavioral Therapy (CBT) / couples sex therapy.
• Deep Etiologies:
  • Endometriosis:
    1. First-line: NSAIDs + Combined OCPs or continuous oral/intrauterine progestins (LNG-IUD).
    2. Second-line: GnRH agonists/antagonists (e.g., Leuprolide with add-back estrogen/progestin, Elagolix).
    3. Refractory / Infertility: Laparoscopic surgical ablation/excision of endometriotic lesions.
  • PID:
    1. First-line Outpatient: Ceftriaxone 500 mg IM single dose + Doxycycline 100 mg PO BID x 14 days + Metronidazole 500 mg PO BID x 14 days.
    2. Inpatient (severe/pregnant/TOA): IV Cefotetan/Cefoxitin + Doxycycline OR IV Ampicillin-Sulbactam + Doxycycline.

---

Complications

• Lichen Sclerosus: Progression to Vulvar Squamous Cell Carcinoma (SCC) (3–5% risk; necessitates lifelong surveillance).
• Endometriosis / PID: Chronic pelvic pain syndrome, extensive pelvic adhesions, tubal occlusion, ectopic pregnancy, and infertility.
• Psychosexual: Secondary Hypoactive Sexual Desire Disorder (HSDD), female orgasmic disorder, severe relationship distress, secondary anxiety/depression.